|
|
Vaccine Detail
|
Melan-A/MAGE-3.DP4 Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Melan-A/MAGE-3.DP4 Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007509
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description: Functional T cells targeting NY-ESO-1 or Melan-A peptides are associated with the survival of patients with distant melanoma metastasis (Weide et al., 2012).
- Detailed Gene Information: Click Here.
- MAGEA3
gene engineering:
- Type: Recombinant protein preparation
- Description: (Weide et al., 2012)
- Detailed Gene Information: Click Here.
- Description: NULL
|
| Host Response |
|
|
| References |
Weide et al., 2012: Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30(15); 1835-1841. [PubMed: 22529253].
|
|
